lirentelimab (AK002)

lirentelimab · Allakos Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for lirentelimab (AK002), covering 2024-09-24 to 2024-09-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria [Phase 2]